left-arrow right-arrow pinterest facebook google_plus linkedin

Breast Cancer Trials

The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the Methodist Health System Trial Code listed with the description.


AFT-38

Status: Recruiting | Phase III

Official Title: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer (PATINA)

Study Purpose: To determine if adding palbociclib to standard treatment with anti-HER2-based therapy plus endocrine therapy is more effective in preventing cancer from getting worse. Learn more.


Alliance A011401

Breast Cancer Weight Loss Study (BWEL Study)

Status: Recruiting | Phase III 

Official Title: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Study Purpose: To determine if losing weight may help prevent breast cancer from coming back. Learn more.


Alliance A011502

Aspirin for Breast Cancer Study (ABC Study)

Status: Recruiting | Phase III 

Official Title: A Randomized Phase III Double-Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for Her2 Negative Breast Cancer.

Study Purpose: To compare the good and bad effects of using aspirin after completing the usual chemotherapy, surgery, and/or radiation therapy for breast cancer. Learn more.


Alliance A171601

Status: Recruiting | Phase II

Official Title: A Phase II Trial Assessing the Tolerability Of Palbociclib In Combination With Letrozole Or Fulvestrant In Patients Aged 70 And Older With Estrogen Receptor Positive, Her2-Negative Metastatic Breast Cancer

Study Purpose: To find out the side effects that the standard, FDA-approved combination treatment of letrozole or fulvestrant and palbociclib has on patients 70 years old and over. Learn more


ECOG-ACRIN EA1131

Status: Recruiting | Phase III

Official Title: Testing Platinum-Based Chemotherapy After Surgery In Triple-Negative Breast Cancers

Study Purpose: To determine if getting more treatment with capecitabine to any good and bad effects of getting more treatment with cisplatin or carboplatin after surgery. The results of this study will provide knowledge as to what approach is better, the same or worse than using capecitabine chemotherapy. Learn more


NRG BR003

Status: Recruiting | Phase III

Official Title: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Study Purpose: To compare the good and bad effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin. Learn more.


NSABP B-51

Status: Recruiting | Phase III

Official Title: Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Study Purpose: To determine whether or not radiation therapy to the lymph nodes is better at keeping breast cancer from returning for patients whose lymph nodes were positive for cancer cells before their chemotherapy (and surgery), but are negative for cancer cells after their chemotherapy. Learn more.


Optimal ODO-TE-B301

Status: Available | Phase III

Official Title: Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane (CONTESSA) 

Study Purpose: To compare and assess the efficacy, safety and tolerability of Tesetaxel plus a reduced dose of Capecitabine alone in patients with HER2 negative, HR positive, LA/MBC previously treated with a Taxane in the neoadjuvant or adjuvant setting. Learn more.


SWOG S1418

Status: Recruiting | Phase III 

Official Title: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

Study Purpose: To determine if adding pembrolizumab to the standard treatment for triple negative breast decrease the risk of the cancer returning (after receiving standard chemotherapy and/or radiation). Learn more. Learn more


SWOG S1706

Status: Recruiting | Phase II

Official Title: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Study Purpose: To determine if adding the drug olaparib to the usual radiation therapy for inflammatory breast cancer will decrease the risk of cancer returning. Learn more.